Following on from information provided to NICE by the company in November 2021 the appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1429 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in November 2021 the appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 13 December 2021 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer. For information, the company have advised that they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 13 May 2021 | Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
| 19 February 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved. |
| 26 May 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
| 24 January 2020 | In progress. Topic is in progress |
| 07 June 2019 - 05 July 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual